VBK Verbio SE
Verbio SE engages in the production and distribution of fuels and finished products in Germany, Europe, North America, and internationally. It operates through Biodiesel, Bioethanol/Biomethane, and Other segments. The company provides bio-based chemicals, biodiesel, pharma-glycerine, biomethane, and bioethanol; olefin metathesis catalysts; animal feeds, such as Verbio Proti Flow and Verbio Grain Pro; phytosterols under the Sterocellent brand name; and fertilizers. It also offers trading, and transport and logistics services. The company's products are used for cosmetics, food, pharmaceuticals, heat and power generation, fuels, renewable chemicals, aromas and fragrances, plastics, agrochemicals, and agriculture applications. It serves oil, oil mills, pharmaceuticals, trading and logistics, transport and fleet operators, energy utilities, farmers, LNG/CNG filling stations/retail, and other sectors. The company was formerly known as VERBIO Vereinigte BioEnergie AG and changed its name to Verbio SE in December 2023. Verbio SE was founded in 2006 and is based in Leipzig, Germany.…
Industry Peers
Specialty ChemicalsKey Statistics
About Verbio (ETR: VBK)
›
Verbio (ETR: VBK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 1,332 employees.
The shares were at 21.60 EUR on 19 November 2026, up 30.3% over 52 weeks. Its 52-week range is 14.95 EUR to 47.26 EUR: the price is 54.3% below the high and 44.5% above the low.
At a market capitalisation of 1.38B EUR, it trades at 13.3 times trailing earnings and 8.4 times forward earnings. The median trailing P/E of its 18 largest Specialty Chemicals peers is 34.0, a discount of 61% for VBK. It pays a dividend yielding 0.86%, against a median of 1.76% among the dividend payers in that peer group.
Verbio reports return on equity of 7.8%, an operating margin of 9.1% and revenue up 24.7% year over year.
Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 45.00 EUR is 108.3% above the current price. The next earnings report is expected on 11 February 2027.